Seattle, WA -- (SBWIRE) -- 11/11/2019 -- The Advisory Committee on Immunization Practices (ACIP) 2017-2018 recommendations mention routine annual influenza vaccination for everyone aged 6 months and above with either inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). The major reasons behind influenza are broad host specificity and high variability of viruses. Moreover, virus neutralizing antibodies induced by various vaccines are strain specific, which leads to vaccinations being updated each year. To tackle this issue, various government and private research organizations are engaged in developing novel vaccines to increase efficacy of these vaccines.
Growing occurrence of seasonal influenza infection in various around the world is expected drive growth of the global seasonal influenza vaccines market during the forecast period. Rising pandemic events of influenza virus and their severity, owing to the genetic diversity of influenza virus is also driving the market growth. According to the World Health Organization (WHO), 2015, around 233 million outpatient visits, 5.2 million hospital admissions, and 7.4 million deaths are expected if a pandemic case were to occur, globally.
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1604
The Centers for Medicare & Medicaid Services (CMS) offers reimbursement covering 100% of the costs of one seasonal influenza virus vaccinations per influenza season, and also covers the seasonal influenza virus vaccinations. Therefore, positive steps for reimbursement taken by regulatory authority and growing incidence of influenza is expected to drive the global seasonal influenza vaccines market over the forecast period.
Furthermore, according to the Indian Journal of Medical Research, June 2016, the influenza A (H1N1) pdm09 outbreak in India caused 30,000 laboratory confirmed cases with over 1,700 deaths from 2009 to 2015.
The World Health Organization (WHO): GISRS (Global Influenza Surveillance and Response System) laboratories from 2 April 2018 to 15 April 2018; tested over 137,071 specimens from various National Influenza centers (NIC) and other national influenza laboratories of 113 countries. Among these collected specimens, 21,639 were positive for influenza viruses, including 12,034 (55.6%) were typed as influenza A and 9,605 (44.4%) as influenza B. According to the data published in European Centre for Disease Prevention and Control (ECDC), in February 2018, around 44,000 people die annually of respiratory diseases associated with seasonal influenza in the European Region, out of a total of up to 6, 50, 000 global deaths, annually.
Moreover, proactive efforts of various government bodies such as the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) with the private sector has led to development of improved influenza vaccines in the U.S. This in turn, has improved influenza pandemic preparedness in the country. Moreover, National Institute of Allergy and Infectious Disease (NIAID) is focused on developing new strategic plan to develop novel, safe, and effective universal influenza vaccine.
For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/1604
Key government agencies in the U.S. are focused on various strategies such as collaboration and partnership, in order to increase the supply of influenza vaccines. For instance, in September 2016, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), to support development of new and better influenza vaccines, as a part of inter-agency government effort in the U.S.
Furthermore, in April 2018, Bill & Melinda Gates Foundation released US$ 12 million grant for Universal Influenza Vaccines Development. The grant is aimed at bringing innovative ideas to treat influenza pandemic infection. Growing initiatives by government and private organizations in the U.S. is expected to drive growth of the seasonal influenza vaccines market.
Moreover, influenza flu vaccination reduces the risk of flu-associated hospitalization among adult and pediatric patients. For instance, according to the Centers for Disease Control and Prevention (CDC), 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S.
Seasonal influenza virus infections could cause significant mortality and morbidity, worldwide. Moreover, current influenza virus vaccines are an effective countermeasure against influenza infection.
However, increasing intergenic variability among various influenza virus strains has led to increasing demand for developing influenza vaccines compatible to all types of influenza virus. For instance, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in February 2018, announced that they are focusing on developing new strategic plan to create safe and effective universal influenza vaccine. NIAID is engaged in developing an influenza vaccine for all age groups against multiple influenza strains, including those which can cause pandemic. Moreover, in June 2017, Seqirus produced cell-based influenza vaccine at commercial scale, using a candidate vaccine virus (CVVs) that has been isolated and grown in cells, rather than in eggs derived virus CVVs. The use of cell-derived CVVs shows the increased potential over the egg-derived CVVs. This has helped in increasing output in the production of cell-based influenza vaccines.
High cost related to manufacturing and complexity of production process, owing to inherent variability of the viral strains are expected to restrain growth of the global seasonal influenza vaccines market during the forecast period. Production of seasonal influenza vaccines is difficult, owing to the slow egg-based manufacturing process, which is currently in use.
Furthermore, Asia Pacific is expected to witness fastest growth over the forecast period. This growth is attributed to large patient pool and increasing focus of key market players to expand in the region. For instance, according to the World Health Organization (WHO), in 2015, there were an estimated 4.74 million new cases of tuberculosis registered and around 8, 00,000 people died due to the tuberculosis and TB and HIV co-infection (TB-HIV) in the South-East Asia region. Moreover, an expected approval of both Daiichi Sankyo's VN-100 and MEDI3250 in 2017, in the Japanese market, is projected to drive seasonal influenza vaccines market in Asia Pacific region.
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1604
Key companies in the market are focused on various growth strategies such as mergers and acquisitions, in order to enhance their presence and gain competitive edge in the market. For instance, in August 2017, Sanofi Pasteur acquired Protein Sciences Corporation, thus adding Flublok products to its portfolio, the only U.S. FDA-approved recombinant protein-based influenza vaccine. With the acquisition, Sanofi expanded its influenza vaccine portfolio and its presence in the global seasonal influenza vaccines market.
Major companies operating in the global seasonal influenza vaccines market are Sanofi S.A., CSL Limited, GlaxoSmithKline Plc., and Medimmune, LLC.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.